China NMPA Clears IND Application for Ph 1/2 Trial of FasTCAR-T GC012F for Treatment of R/R Multiple Myeloma
“This milestone marks successful regulatory clearances to commence key clinical trials for Gracell’s lead asset, GC012F, in both China and the United States,” said Dr. William (Wei) Cao, founder, Chairman, and CEO of Gracell. “We believe GC012F has vast potential to meaningfully improve cancer care, including the faster delivery to patients enabled by Gracell’s FasTCAR next-day manufacturing and a novel approach of BCMA and CD19 dual-targeting in multiple indications. Gracell is committed to developing innovative cell therapies to transform patients’ lives, and we look forward to launching the Phase 1/2 IND trial in China to further study GC012F.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo